Janssen R&D Ireland

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Janssen R&D Ireland sits in the top decile of US sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count).

14 total trials none currently recruiting 14 completed later-stage tilt top decile by trial count

Janssen R&D Ireland: 14 sponsored US clinical trials, none currently recruiting.

Janssen R&D Ireland sponsors 14 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 14 completed. 10 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hepatitis C Virus Genotype-1, with 1 trials.

Top-decile sponsor footprint

Janssen R&D Ireland ranks in the top decile of sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

14 of 14 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

14 total, page 1 of 1

COMPLETED Phase 3

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

NCT02269917
COMPLETED Phase 1

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants.

NCT02018536
COMPLETED Phase 1

A Study to Explore Pharmacokinetic Interaction Between Rilpivirine and Metformin in Healthy Participants

NCT01719614
COMPLETED Phase 3

TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy

NCT01485991
COMPLETED Phase 2

A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients

NCT01466790
COMPLETED Phase 3

A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study

NCT01323244
COMPLETED Phase 3

A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1

NCT01479868
COMPLETED Phase 4

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients

NCT01422330
COMPLETED Phase 3

3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection

NCT01349465
COMPLETED Phase 3

An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants

NCT01290679
COMPLETED Phase 3

An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy

NCT01281839
COMPLETED Phase 3

An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients

NCT01289782
COMPLETED Phase 3

A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1

NCT01266902
COMPLETED Phase 2

TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients

NCT00896051

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 2
Phase 3 9
Phase 4 1

Therapeutic Areas

Hepatitis C Virus Genotype-1 1
Hepatitis C 1

How the Janssen R&D Ireland archive is shaped

14 indexed studies, none listed as recruiting (0% open); 14 completed (100%).

Phase mix: 10 late (III/IV) vs 4 early (I/II) (later-stage heavy).

Top condition: Hepatitis C Virus Genotype-1 (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Janssen R&D Ireland: archived-pipeline peers nationwide

Peers matched on 14 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Janssen R&D Ireland sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share Janssen R&D Ireland3-C Institute for Social DevelopmentAbbott Medical OpticsAbbott RDx CardiometabolicAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA10xBio22nd Century Group23andMe3 Waves Wellness
Janssen R&D Ireland sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Janssen R&D Ireland sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 14 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Janssen R&D Ireland page

14 registered trials is a research-attention snapshot, not an endorsement of Janssen R&D Ireland or any single study.

  • None of Janssen R&D Ireland's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Hepatitis C Virus Genotype-1 is the condition Janssen R&D Ireland studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hepatitis C Virus Genotype-1 trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Janssen R&D Ireland pipeline card: 14 registered trials from official public datasets.Report a data error.